Tapentadol PR for Pain Syndromes in Real Life Patients with Hematological Malignancy.

Background: More than 50% of oncohematological patients suffer from pain syndrome, mostly originating from the bone, which often include nociceptive and neuropathic complaints. Tapentadol, a recently available treatment option for cancer pain, exerts a dual analgesic mechanisms (opioid and noradrenergic), allowing for a high clinical efficacy as well as for a reduction in adverse events compared to traditional opioids.

Aim: To explore the safety and efficacy of tapentadol as a suitable agent for the pain management in the setting of oncohematology.